Rs 11 IV Set Sold For Rs 325: Tukaram Mundhe Asks Centre To Intervene
A market survey by the Maharashtra FDA has revealed extreme price mark-ups on essential medical devices, with some items sold to patients at over 2,800% of their procurement cost. Commissioner Tukaram Mundhe has called for central government intervention to curb this profiteering.
Why it matters
This highlights systemic issues in healthcare affordability and the need for stricter regulation of medical device pricing in India.
An IV (intravenous) set costing Rs 11 is sold to a bedridden patient at Rs 325, representing a profit margin of over 2,800 per cent.A 10 ml syringe costing Rs 6.75 is sold for Rs 57.20, an exorbitant mark-up of 747 per cent.An IV cannula priced at Rs 22.50 is sold for Rs 424, nearly 19 times its procurement cost.A nebulizer mask costing Rs 40 is billed at Rs 715, a mark-up of 1,687 per cent.These are not just numbers. They are the findings of an extensive market survey conducted by the Maharashtra State Price Monitoring Resource Unit (MSPMRU) under the state Food and Drugs Administration (FDA) to assess pricing patterns of medical devices sold in retail and trade markets.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in